Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.

Yoshiyuki YamamotoHiroki YukamiTatsuro YamaguchiHisatsugu OhoriSachiko NagasuYoshinori KagawaNaotoshi SugimotoHiromichi SonodaKentaro YamazakiAtsuo TakashimaHiroyuki OkuyamaHiroko HasegawaChihiro KondoEishi BabaToshihiko MatsumotoYasuyuki KawamotoMasato KataokaYoshiaki ShindoToshiaki IshikawaTaito EsakiYosuke KitoTakeo SatoTaro FunakoshiToshifumi YamaguchiYasuhiro ShimadaToshikazu Moriwaki

Published in: International journal of clinical oncology (2024)

In a real-world clinical setting, FOLFOXIRI plus bevacizumab demonstrated efficacy and safety comparable to previous clinical trials.

Keyphrases

metastatic colorectal cancer
clinical trial
metabolic syndrome
skeletal muscle
adipose tissue
insulin resistance
open label
double blind
placebo controlled